|
|
|
|
| LEADER |
05797nma a2201873 u 4500 |
| 001 |
EB002045331 |
| 003 |
EBX01000000000000001188997 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a books978-3-0365-4347-5
|
| 020 |
|
|
|a 9783036543482
|
| 020 |
|
|
|a 9783036543475
|
| 100 |
1 |
|
|a Meegan, Mary J
|
| 245 |
0 |
0 |
|a Anticancer Drugs 2021
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
| 300 |
|
|
|a 1 electronic resource (594 p.)
|
| 653 |
|
|
|a age
|
| 653 |
|
|
|a dual inhibitors
|
| 653 |
|
|
|a multidrug resistance
|
| 653 |
|
|
|a CAR (chimeric antigen receptor)
|
| 653 |
|
|
|a miR-21
|
| 653 |
|
|
|a mechanism prediction
|
| 653 |
|
|
|a TDP1
|
| 653 |
|
|
|a model informed dosing
|
| 653 |
|
|
|a enantioselective synthesis
|
| 653 |
|
|
|a hydrazide derivatives
|
| 653 |
|
|
|a entrectinib
|
| 653 |
|
|
|a dual-targeting molecule
|
| 653 |
|
|
|a Toll-Like Receptor
|
| 653 |
|
|
|a mucin
|
| 653 |
|
|
|a cancer vaccine
|
| 653 |
|
|
|a testis
|
| 653 |
|
|
|a larotrectinib
|
| 653 |
|
|
|a physiologically based pharmacokinetics
|
| 653 |
|
|
|a Bcl-2 inhibitors
|
| 653 |
|
|
|a thymidylate synthase
|
| 653 |
|
|
|a HER2
|
| 653 |
|
|
|a MUC16
|
| 653 |
|
|
|a generic product
|
| 653 |
|
|
|a cytotoxic agents
|
| 653 |
|
|
|a STAT inhibitors
|
| 653 |
|
|
|a immunotherapy
|
| 653 |
|
|
|a sorafenib
|
| 653 |
|
|
|a 1,2,3-triazole
|
| 653 |
|
|
|a trypan blue assay
|
| 653 |
|
|
|a chalcones
|
| 653 |
|
|
|a pemetrexed
|
| 653 |
|
|
|a combretastatin A-4
|
| 653 |
|
|
|a tubulin polymerisation inhibitor
|
| 653 |
|
|
|a cyclophosphamide
|
| 653 |
|
|
|a doxazosin
|
| 653 |
|
|
|a tryptophanol
|
| 653 |
|
|
|a hybrid molecule
|
| 653 |
|
|
|a phenstatin
|
| 653 |
|
|
|a exportin-1
|
| 653 |
|
|
|a apoptosis induction
|
| 653 |
|
|
|a covalent binding
|
| 653 |
|
|
|a designed multiple ligand
|
| 653 |
|
|
|a Research & information: general / bicssc
|
| 653 |
|
|
|a 3-amino-4'-guanidino
|
| 653 |
|
|
|a benzenesulfonamides
|
| 653 |
|
|
|a mitoxantrone
|
| 653 |
|
|
|a H1299
|
| 653 |
|
|
|a alkylated
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a Indole-based analogues
|
| 653 |
|
|
|a BRAF
|
| 653 |
|
|
|a cardiotoxicity
|
| 653 |
|
|
|a interleukin-6
|
| 653 |
|
|
|a indazole
|
| 653 |
|
|
|a cancer cell viability
|
| 653 |
|
|
|a NaMSA
|
| 653 |
|
|
|a CovDock
|
| 653 |
|
|
|a nucleoside
|
| 653 |
|
|
|a cytotoxicity
|
| 653 |
|
|
|a ADC (antibody-drug conjugate)
|
| 653 |
|
|
|a patent review
|
| 653 |
|
|
|a docking
|
| 653 |
|
|
|a concentration-guided dosing
|
| 653 |
|
|
|a hybrid compounds
|
| 653 |
|
|
|a toxicity
|
| 653 |
|
|
|a cumulative dose
|
| 653 |
|
|
|a adamantane
|
| 653 |
|
|
|a chalcone
|
| 653 |
|
|
|a gastric adenocarcinoma
|
| 653 |
|
|
|a cytotoxic activity
|
| 653 |
|
|
|a drug efflux
|
| 653 |
|
|
|a tyrosil-DNA-phosphodiesterase 1
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a solid/lipid nanoparticles
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a carvedilol
|
| 653 |
|
|
|a thiourea
|
| 653 |
|
|
|a 3,4'-bis-guanidino
|
| 653 |
|
|
|a acetamide
|
| 653 |
|
|
|a tumor spheroids
|
| 653 |
|
|
|a cell cycle analysis
|
| 653 |
|
|
|a Imiquimod
|
| 653 |
|
|
|a benzimidazole
|
| 653 |
|
|
|a protein kinase inhibitors
|
| 653 |
|
|
|a 1,3,4-oxadiazole
|
| 653 |
|
|
|a 7-deaza-4'-thioadenosine derivatives
|
| 653 |
|
|
|a DNA fragmentation
|
| 653 |
|
|
|a NTRK
|
| 653 |
|
|
|a heterocyclic compound
|
| 653 |
|
|
|a 5-fluoruracil
|
| 653 |
|
|
|a intramolecular hydrogen bond
|
| 653 |
|
|
|a anticancer
|
| 653 |
|
|
|a urinary bladder
|
| 653 |
|
|
|a imidazoles
|
| 653 |
|
|
|a anticancer activity
|
| 653 |
|
|
|a apoptosis
|
| 653 |
|
|
|a multi-kinase inhibitor
|
| 653 |
|
|
|a breast cancer
|
| 653 |
|
|
|a phenyl pyridyl ether
|
| 653 |
|
|
|a histopathology
|
| 653 |
|
|
|a MDA-MB-231 cells
|
| 653 |
|
|
|a in vitro
|
| 653 |
|
|
|a xanthone
|
| 653 |
|
|
|a tissue-agnostic
|
| 653 |
|
|
|a anticancer agents
|
| 653 |
|
|
|a kidney
|
| 653 |
|
|
|a HL-60
|
| 653 |
|
|
|a MD simulations
|
| 653 |
|
|
|a nitrogen scaffolds
|
| 653 |
|
|
|a ELISA
|
| 653 |
|
|
|a synthesis
|
| 653 |
|
|
|a isolation
|
| 653 |
|
|
|a EGFR
|
| 653 |
|
|
|a HDAC inhibitors
|
| 653 |
|
|
|a MTT cytotoxic assay
|
| 653 |
|
|
|a HT-29 cells
|
| 653 |
|
|
|a MUC1
|
| 653 |
|
|
|a USFDA
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a in vivo
|
| 653 |
|
|
|a thieno[2,3-d][1,2,3]triazine
|
| 653 |
|
|
|a resin acid
|
| 653 |
|
|
|a Trk
|
| 653 |
|
|
|a Trk fusion
|
| 653 |
|
|
|a aromatase inhibitor
|
| 653 |
|
|
|a Chemistry / bicssc
|
| 653 |
|
|
|a letrozole
|
| 653 |
|
|
|a colony formation
|
| 653 |
|
|
|a diphenyl ether
|
| 700 |
1 |
|
|a O'Boyle, Niamh M
|
| 700 |
1 |
|
|a Meegan, Mary J
|
| 700 |
1 |
|
|a O'Boyle, Niamh M
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-0365-4347-5
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/84569
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/5551
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 000
|
| 082 |
0 |
|
|a 540
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure-activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.
|